Pulmonologists’ Opinion on the Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Patients in Spain: A Cross-Sectional Survey
Marc Miravitlles,1,2 Fernando González-Torralba,3 Cristina Represas-Represas,4 Xavier Pomares,2,5 Eduardo Márquez-Martín,2,6 Cruz González,7 Carlos Amado,8 Carles Forné,9,10 Soledad Alonso,11 Bernardino Alcázar,12 Miriam Barrecheguren,1 Juan María Jurado Mirete,13 Elsa Naval14 1Pneumology Department...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2022-07-01
|
| Series: | International Journal of COPD |
| Subjects: | |
| Online Access: | https://www.dovepress.com/pulmonologists-opinion-on-the-use-of-inhaled-corticosteroids-in-chroni-peer-reviewed-fulltext-article-COPD |
| _version_ | 1811225882614824960 |
|---|---|
| author | Miravitlles M González-Torralba F Represas-Represas C Pomares X Márquez-Martín E González C Amado C Forné C Alonso S Alcázar B Barrecheguren M Jurado Mirete JM Naval E |
| author_facet | Miravitlles M González-Torralba F Represas-Represas C Pomares X Márquez-Martín E González C Amado C Forné C Alonso S Alcázar B Barrecheguren M Jurado Mirete JM Naval E |
| author_sort | Miravitlles M |
| collection | DOAJ |
| description | Marc Miravitlles,1,2 Fernando González-Torralba,3 Cristina Represas-Represas,4 Xavier Pomares,2,5 Eduardo Márquez-Martín,2,6 Cruz González,7 Carlos Amado,8 Carles Forné,9,10 Soledad Alonso,11 Bernardino Alcázar,12 Miriam Barrecheguren,1 Juan María Jurado Mirete,13 Elsa Naval14 1Pneumology Department, Hospital Universitari Vall d’Hebron, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain; 2CIBER de Enfermedades Respiratorias (CIBERES), ISCIII, Madrid, Spain; 3Pneumology Department, Hospital Universitario del Tajo, Aranjuez, Spain; 4Pneumology Department, Hospital Álvaro Cunqueiro, Vigo, Spain; 5Pneumology Department, Corporació Sanitària Parc Taulí, Sabadell, Spain; 6Medical-Surgical Unit for Respiratory Diseases, Hospital Universitario Virgen del Rocío, Sevilla, Spain; 7Pneumology Department, Hospital Clínico de Valencia, Valencia, Spain; 8Pneumology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain; 9Heorfy Consulting, Lleida, Spain; 10Basic Medical Sciences Department, University of Lleida, Lleida, Spain; 11Pneumology Department, Hospital Universitario de Torrejón, Torrejón de Ardoz, Spain; 12Pneumology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain; 13Scientific Department, GOC Health Consulting, Barcelona, Spain; 14Pneumology Department, Hospital Universitario de La Ribera, Alzira, SpainCorrespondence: Marc Miravitlles, Pneumology Department, Hospital Universitari Vall d’Hebron, P. Vall d’Hebron 119-129, Barcelona, 08035, Spain, Tel/Fax +34 932746083, Email marcm@separ.esIntroduction: Identifying the variables that guide decision-making in relation to the use of inhaled corticosteroids (ICS) can contribute to the appropriate use of these drugs. The objective of this study was to identify the clinical variables that physicians consider most relevant for prescribing or withdrawing ICS in COPD.Methods: A cross-sectional survey was conducted in Spain from November 2020 to May 2021. Therapeutic decisions on the use of ICS in 11 hypothetical COPD patient profiles were collected using an online survey answered by specialists with experience in the management of patients with COPD. Mixed-effects logistic regression was used to analyze the impact of patients’ characteristics in the therapeutic decision for prescribing ICS or proceeding to its withdrawal.Results: A total of 74 pulmonologists agreed to collaborate in the survey and answered the questionnaire. The results showed great variability, with only 2 profiles achieving consensus for starting or withdrawing the treatment. The frequency and severity of exacerbations influenced the decision to prescribe ICS in a dose-response fashion (1 exacerbation odds ratio (OR) = 1.86, 95% confidence interval (CI) 1.02 to 3.43, two exacerbations OR = 11.6, 95% CI: 4.47 to 30.2 and three OR = 123, 95% CI: 25 to 601). Similarly, increasing blood eosinophils and history of asthma were associated with ICS use. On the other hand, pneumonia reduced the probability of initiating treatment with ICS (OR = 0.54 [0.29 to 0.98]). Lung function and dyspnea degree did not influence the clinician’s therapeutic decision. The results for withdrawal of ICS were similar but in the opposite direction.Conclusion: In accordance with guidelines, exacerbations, blood eosinophils and history of asthma or pneumonia are the factors considered by pulmonologist for the indication or withdrawal of ICS. However, the agreement in prescription or withdrawal of ICS when confronted with hypothetical cases is very low, suggesting a great variability in clinical practice.Keywords: COPD, exacerbation, bronchodilators, inhaled corticosteroids, eosinophils, withdrawal |
| first_indexed | 2024-04-12T09:14:45Z |
| format | Article |
| id | doaj.art-3e6c154e63284abb88ffda6e3d48402e |
| institution | Directory Open Access Journal |
| issn | 1178-2005 |
| language | English |
| last_indexed | 2024-04-12T09:14:45Z |
| publishDate | 2022-07-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of COPD |
| spelling | doaj.art-3e6c154e63284abb88ffda6e3d48402e2022-12-22T03:38:52ZengDove Medical PressInternational Journal of COPD1178-20052022-07-01Volume 171577158776522Pulmonologists’ Opinion on the Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Patients in Spain: A Cross-Sectional SurveyMiravitlles MGonzález-Torralba FRepresas-Represas CPomares XMárquez-Martín EGonzález CAmado CForné CAlonso SAlcázar BBarrecheguren MJurado Mirete JMNaval EMarc Miravitlles,1,2 Fernando González-Torralba,3 Cristina Represas-Represas,4 Xavier Pomares,2,5 Eduardo Márquez-Martín,2,6 Cruz González,7 Carlos Amado,8 Carles Forné,9,10 Soledad Alonso,11 Bernardino Alcázar,12 Miriam Barrecheguren,1 Juan María Jurado Mirete,13 Elsa Naval14 1Pneumology Department, Hospital Universitari Vall d’Hebron, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain; 2CIBER de Enfermedades Respiratorias (CIBERES), ISCIII, Madrid, Spain; 3Pneumology Department, Hospital Universitario del Tajo, Aranjuez, Spain; 4Pneumology Department, Hospital Álvaro Cunqueiro, Vigo, Spain; 5Pneumology Department, Corporació Sanitària Parc Taulí, Sabadell, Spain; 6Medical-Surgical Unit for Respiratory Diseases, Hospital Universitario Virgen del Rocío, Sevilla, Spain; 7Pneumology Department, Hospital Clínico de Valencia, Valencia, Spain; 8Pneumology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain; 9Heorfy Consulting, Lleida, Spain; 10Basic Medical Sciences Department, University of Lleida, Lleida, Spain; 11Pneumology Department, Hospital Universitario de Torrejón, Torrejón de Ardoz, Spain; 12Pneumology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain; 13Scientific Department, GOC Health Consulting, Barcelona, Spain; 14Pneumology Department, Hospital Universitario de La Ribera, Alzira, SpainCorrespondence: Marc Miravitlles, Pneumology Department, Hospital Universitari Vall d’Hebron, P. Vall d’Hebron 119-129, Barcelona, 08035, Spain, Tel/Fax +34 932746083, Email marcm@separ.esIntroduction: Identifying the variables that guide decision-making in relation to the use of inhaled corticosteroids (ICS) can contribute to the appropriate use of these drugs. The objective of this study was to identify the clinical variables that physicians consider most relevant for prescribing or withdrawing ICS in COPD.Methods: A cross-sectional survey was conducted in Spain from November 2020 to May 2021. Therapeutic decisions on the use of ICS in 11 hypothetical COPD patient profiles were collected using an online survey answered by specialists with experience in the management of patients with COPD. Mixed-effects logistic regression was used to analyze the impact of patients’ characteristics in the therapeutic decision for prescribing ICS or proceeding to its withdrawal.Results: A total of 74 pulmonologists agreed to collaborate in the survey and answered the questionnaire. The results showed great variability, with only 2 profiles achieving consensus for starting or withdrawing the treatment. The frequency and severity of exacerbations influenced the decision to prescribe ICS in a dose-response fashion (1 exacerbation odds ratio (OR) = 1.86, 95% confidence interval (CI) 1.02 to 3.43, two exacerbations OR = 11.6, 95% CI: 4.47 to 30.2 and three OR = 123, 95% CI: 25 to 601). Similarly, increasing blood eosinophils and history of asthma were associated with ICS use. On the other hand, pneumonia reduced the probability of initiating treatment with ICS (OR = 0.54 [0.29 to 0.98]). Lung function and dyspnea degree did not influence the clinician’s therapeutic decision. The results for withdrawal of ICS were similar but in the opposite direction.Conclusion: In accordance with guidelines, exacerbations, blood eosinophils and history of asthma or pneumonia are the factors considered by pulmonologist for the indication or withdrawal of ICS. However, the agreement in prescription or withdrawal of ICS when confronted with hypothetical cases is very low, suggesting a great variability in clinical practice.Keywords: COPD, exacerbation, bronchodilators, inhaled corticosteroids, eosinophils, withdrawalhttps://www.dovepress.com/pulmonologists-opinion-on-the-use-of-inhaled-corticosteroids-in-chroni-peer-reviewed-fulltext-article-COPDcopdexacerbationbronchodilatorsinhaled corticosteroidseosinophilswithdrawal. |
| spellingShingle | Miravitlles M González-Torralba F Represas-Represas C Pomares X Márquez-Martín E González C Amado C Forné C Alonso S Alcázar B Barrecheguren M Jurado Mirete JM Naval E Pulmonologists’ Opinion on the Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Patients in Spain: A Cross-Sectional Survey International Journal of COPD copd exacerbation bronchodilators inhaled corticosteroids eosinophils withdrawal. |
| title | Pulmonologists’ Opinion on the Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Patients in Spain: A Cross-Sectional Survey |
| title_full | Pulmonologists’ Opinion on the Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Patients in Spain: A Cross-Sectional Survey |
| title_fullStr | Pulmonologists’ Opinion on the Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Patients in Spain: A Cross-Sectional Survey |
| title_full_unstemmed | Pulmonologists’ Opinion on the Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Patients in Spain: A Cross-Sectional Survey |
| title_short | Pulmonologists’ Opinion on the Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Patients in Spain: A Cross-Sectional Survey |
| title_sort | pulmonologists rsquo opinion on the use of inhaled corticosteroids in chronic obstructive pulmonary disease patients in spain a cross sectional survey |
| topic | copd exacerbation bronchodilators inhaled corticosteroids eosinophils withdrawal. |
| url | https://www.dovepress.com/pulmonologists-opinion-on-the-use-of-inhaled-corticosteroids-in-chroni-peer-reviewed-fulltext-article-COPD |
| work_keys_str_mv | AT miravitllesm pulmonologistsrsquoopinionontheuseofinhaledcorticosteroidsinchronicobstructivepulmonarydiseasepatientsinspainacrosssectionalsurvey AT gonzaleztorralbaf pulmonologistsrsquoopinionontheuseofinhaledcorticosteroidsinchronicobstructivepulmonarydiseasepatientsinspainacrosssectionalsurvey AT represasrepresasc pulmonologistsrsquoopinionontheuseofinhaledcorticosteroidsinchronicobstructivepulmonarydiseasepatientsinspainacrosssectionalsurvey AT pomaresx pulmonologistsrsquoopinionontheuseofinhaledcorticosteroidsinchronicobstructivepulmonarydiseasepatientsinspainacrosssectionalsurvey AT marquezmartine pulmonologistsrsquoopinionontheuseofinhaledcorticosteroidsinchronicobstructivepulmonarydiseasepatientsinspainacrosssectionalsurvey AT gonzalezc pulmonologistsrsquoopinionontheuseofinhaledcorticosteroidsinchronicobstructivepulmonarydiseasepatientsinspainacrosssectionalsurvey AT amadoc pulmonologistsrsquoopinionontheuseofinhaledcorticosteroidsinchronicobstructivepulmonarydiseasepatientsinspainacrosssectionalsurvey AT fornec pulmonologistsrsquoopinionontheuseofinhaledcorticosteroidsinchronicobstructivepulmonarydiseasepatientsinspainacrosssectionalsurvey AT alonsos pulmonologistsrsquoopinionontheuseofinhaledcorticosteroidsinchronicobstructivepulmonarydiseasepatientsinspainacrosssectionalsurvey AT alcazarb pulmonologistsrsquoopinionontheuseofinhaledcorticosteroidsinchronicobstructivepulmonarydiseasepatientsinspainacrosssectionalsurvey AT barrechegurenm pulmonologistsrsquoopinionontheuseofinhaledcorticosteroidsinchronicobstructivepulmonarydiseasepatientsinspainacrosssectionalsurvey AT juradomiretejm pulmonologistsrsquoopinionontheuseofinhaledcorticosteroidsinchronicobstructivepulmonarydiseasepatientsinspainacrosssectionalsurvey AT navale pulmonologistsrsquoopinionontheuseofinhaledcorticosteroidsinchronicobstructivepulmonarydiseasepatientsinspainacrosssectionalsurvey |